【ChiCTR-ONRC-10000909】利用組織多普勒超聲波, 對早期的右心室功能不全, 以及其對左心室功能的影響, 進行一系列的超聲波評估

查看原文

立即下载

基本信息

登记号

ChiCTR-ONRC-10000909

试验状态

暂停或中断

药物名称

药物类型

规范名称

首次公示信息日的期

2010-06-04

临床申请受理号

靶点

适应症

Chronic obstructive pulmonary disease (COPD)

试验通俗题目

利用組織多普勒超聲波, 對早期的右心室功能不全, 以及其對左心室功能的影響, 進行一系列的超聲波評估

试验专业题目

利用組織多普勒超聲波, 對早期的右心室功能不全, 以及其對左心室功能的影響, 進行一系列的超聲波評估

申办单位信息

申请人联系人

请登录查看

申请人名称

请登录查看

联系人邮箱

请登录查看

联系人邮编

联系人通讯地址

请登录查看

临床试验信息

试验目的

Serial Echocardiographic Assessment of Early Right Ventricular Dysfunction by Tissue Doppler Echocardiography & its Impact on Left Ventricular Function.

试验分类

请登录查看

试验类型

非随机对照试验

试验分期

Ⅳ期

随机化

盲法

试验项目经费来源

RGC funding for the study

试验范围

目标入组人数

实际入组人数

第一例入组时间

2006-03-27

试验终止时间

1990-01-01

是否属于一致性

入选标准

1) Patients diagnosed with COPD who are stable (without history of acute exacerbation of COPD in the past 3 months before enrolment); and 2) Objective evidence of abnormal and obstructive lung function by spirometry, with FEV1 between 30-80% of normal age-predicted value and FEV1/FVC ratio <70%.；

排除标准

1) COPD with history of hospitalization due to acute exacerbation within the past 3 months; 2) COPD who are dependent on assisted ventilation of any kind that may affect cardiac function; 3) Patients who have other interstitial lung disease, e.g. pneumoconiosis, bronchiectasis, alveolar fibrosis, etc; 4) Patients with other active lung pathologies, such as primary or secondary lung malignancies, pneumonia, active tuberculosis, pleural effusion, etc; 5) Patients with primary pulmonary hypertension; 6) Patients with secondary pulmonary hypertension other than due to COPD, such as thromboembolism; 7) Patients who known structural heart disease, such as coronary heart disease, left ventricular hypertrophy, significant valvular heart disease, cardiomyopathies, etc; 8) Patients with active cardiac arrhythmias such as atrial fibrillation; 9) Patients with active systemic illness or end-organ disease that may affect cardiac or pulmonary function, such as renal or liver failure; 10) Patients with disease with expected life expectancy <1 year, such as malignancies; 11) Patients who refuse to participate the study.；

研究者信息

研究负责人姓名

请登录查看

试验机构

RGC funding

研究负责人电话

请登录查看

研究负责人邮箱

请登录查看

研究负责人邮编

联系人通讯地址

请登录查看